Division of Medical Ethics, Department of Public Health, Weill Cornell Medical College, New York, NY 10065, USA.
J Med Ethics. 2010 Aug;36(8):483-7. doi: 10.1136/jme.2010.036095.
Recent advances in biotechnologies have led to speculations about enhancing human beings. Many of the moral arguments presented to defend human enhancement technologies have been limited to discussions of their risks and benefits. The author argues that in so far as ethical arguments focus primarily on risks and benefits of human enhancement technologies, these arguments will be insufficient to provide a robust defence of these technologies. This is so because the belief that an assessment of risks and benefits is a sufficient ethical evaluation of these technologies incorrectly presupposes that risk assessments do not involve value judgements. Second, it presupposes a reductionist conception of ethics as merely a risk management instrument. Each of these assumptions separates ethical evaluation from discussion and appraisal of ends and means and thus leaves important--indeed, essential--ethical considerations out of view. Once these problematic assumptions are rejected, it becomes clear that an adequate defence of human enhancement technologies requires more than a simple balance of their risks and benefits.
生物技术的最新进展引发了关于人类增强的种种猜测。许多用来捍卫人类增强技术的道德论点仅限于讨论其风险和收益。作者认为,只要伦理论点主要集中在人类增强技术的风险和收益上,这些论点就不足以对这些技术提供强有力的辩护。之所以如此,是因为风险评估不涉及价值判断的观点错误地假设,对风险和收益的评估是对这些技术进行伦理评估的充分条件。第二,它假设了伦理作为仅仅是一种风险管理工具的简化概念。这些假设中的每一个都将伦理评估与目的和手段的讨论和评价分开,从而忽略了重要的——事实上是必不可少的——伦理考虑。一旦这些有问题的假设被拒绝,就很明显,对人类增强技术的充分辩护需要的不仅仅是简单地平衡其风险和收益。